The cost of treating skeletal-related events in patients with prostate cancer

American Journal of Managed Care

Volumn 14, Issue 5, 2008, Pages 317-322

  Lage, Maureen J ^a   Barber, Beth L ^b   Harrison, David J ^b   Jun, Sun ^b  

^a HealthMetrics Outcomes Research LLC   (United States)

^b AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; BONE METASTASIS; CANCER PATIENT; COST OF ILLNESS; HEALTH CARE COST; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; ORTHOPEDIC SURGERY; PATHOLOGIC FRACTURE; PRIORITY JOURNAL; PROSTATE CANCER; RETROSPECTIVE STUDY; BONE DISEASE; CANCER RADIOTHERAPY; CONFIDENCE INTERVAL; ECONOMIC ASPECT; HEALTH INSURANCE; INCIDENCE;

ADULT; AGED; BONE NEOPLASMS; FRACTURES, SPONTANEOUS; HEALTH CARE COSTS; HUMANS; INSURANCE CLAIM REVIEW; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; UNITED STATES;

EID: 43949146650     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Hsing AW, Chokkalingam AP. Prostate cancer epidemiology. Front Biosci. 2006;11:1388-1413.
2. Sharifi N, Gulley J, Dahut WL. Androgen deprivation therapy for prostate cancer. JAMA. 2005;294(2):238-244.
3. Stewart AB, Lwaleed BA, Douglas DA, Birch BR. Current drug therapy for prostate cancer: an overview. Curr Med Anticancer Agents. 2005;5(6):603-612.
4. American Cancer Society. Cancer facts & figures 2007: estimated new cancer cases and deaths by sex for all sites, US, 2007. http://www.cancer.org/downloads/STT/CAFF2007PWSecured.pdf. Accessed February 6, 2007.
5. Yuen KK, Shelley M, Sze WM, Wilt T, Mason MD. Bisphosphonates for advanced prostate cancer. Cochrane Database Syst Rev. 2006;4:CD006250.
6. Tubaro A, De Nunzio C. Bone health in prostate cancer patients. Business Briefing: European Kidney and Urological Disease 2006. http://www.touchbriefings.com/pdf/1599/Tubaro.pdf. Accessed December 14, 2007.
7. Higher costs may justify prophylaxis in prostate and lung cancer patients with bone metastases. J Support Oncol. 2004;2(5):456.
8. Drudge-Coates L. Skeletal complications and the use of bisphosphonates in metastatic prostate cancer. Int J Palliat Nurs. 2006;12(10):462-469.
9. Delea T, McKiernan J, Brandman J, et al. Retrospective study of the effect of skeletal complications on total medical care costs in patients with bone metastases of breast cancer seen in typical clinical practice. J Support Oncol. 2006;4(7):341-347.
10. Lipton A. Management of bone metastases in breast cancer. Curr Treat Options Oncol. 2005;6(2):161-171.
11. LoRusso P. Analysis of skeletal-related events in breast cancer and response to therapy. Semin Oncol. 2001;28(4 suppl 11):22-27.
12. Coleman RE. Skeletal complications of malignancy. Cancer. 1997;80(8 Suppl):1588-1594.
13. Clemons MJ, Dranitsaris G, Ooi WS, et al. Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy. J Clin Oncol. 2006;24(30):4895-4900.
14. Wardley A, Davidson N, Barrett-Lee P, et al. Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomised, crossover study of community vs hospital bisphosphonate administration. Br J Cancer. 2005;92(10):1869-1876.
15. Karamouzis MV, Ioannidis G, Rigatos G. Quality of life in metastatic breast cancer patients under chemotherapy or supportive care: a single-institution comparative study. Eur J Cancer Care (Engl). 2007;16(5):433-438.
16. Manders K, van de Poll-Franse LV, Creemers GJ, et al. Clinical management of women with metastatic breast cancer: a descriptive study according to age group. BMC Cancer. 2006;6:e179.
17. Ito Y, Tokudome N. Chemotherapy for metastatic breast cancer [in Japanese], Gan To Kagaku Ryoho. 2006;33(6):742-746.
18. McMillan SC. Quality-of-life assessment in palliative care. Cancer Control J. 1996;e3. http://moffitt.org/moffittapps/ccj/v3n3/ article4.html. Accessed December 14, 2007.
19. Groot MT, Boeken Kruger CG, Pelger RC, Uyl-de Groot CA. Costs of prostate cancer, metastatic to the bone, in the Netherlands. Eur Urol. 2003;43(3):226-232.
20. Delea T, Langer C, McKiernan J, et al. The cost of treatment of skeletal-related events in patients with bone metastases from lung cancer. Oncology. 2004;67(5-6):390-396.
21. Botteman M, Barghout V, Stephens J, Hay J, Brandman J, Aapro M. Cost effectiveness of bisphosphonates in the management of breast cancer patients with bone metastases. Ann Oncol. 2006;17(7):1072-1082.
22. Lamy O, Burckhardt P. Hypercalcemia of malignancy: diagnosis and treatment options. Am J Cancer. 2002;1(4):277-292.
23. Lamy O, Jenzer-Closuit A, Burckhardt P. Hypercalcemia of malignancy: an undiagnosed and undertreated disease. J Intern Med. 2001;250(1):73-79.
24. Fisher JA, Fikry C, Troxel AB. Cutting cost and increasing access to colorectal cancer screening: another approach to following the guidelines. Cancer Epidemiol Biomarkers Prev. 2006;15(1):108-113.
25. Rex DK, Imperiale TF, Latinovich DR, Bratcher LL. Impact of bowel preparation on efficiency and costs of colonoscopy. Am J Gastroenterol. 2002;97(7):1696-1700.
26. Lin DY, Feuer EJ, Etzioni R, Wax Y. Estimating costs from incomplete follow-up data. Biometrics. 1997;53(2):419-434.
27. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-383.
28. Hillner BE, Weeks JC, Desch CE, Smith TJ. Pamidronate in prevention of bone complications in metastatic breast cancer: a cost-effectiveness analysis. J Clin Oncol. 2000;18(1):72-79.
29. DePuy V, Anstrom KJ, Castel LD, Schulman KA, Weinfurt KP, Saad F. Effects of skeletal morbidities on longitudinal patient-reported outcomes and survival in patients with metastatic prostate cancer. Support Care Cancer. 2007;15(7):869-876.
30. Schröder FH, de Vries SH, Bangma CH. Watchful waiting in prostate cancer: review and policy proposals. BJU Int. 2003;92(8):851-859.
31. Gonzalez EC, Ferrante JM, Van Durme DJ, Pal N, Roetzheim RG. Comorbid illness and the early detection of cancer. South Med J. 2001;94(9):913-920.
32. Cooper C. The crippling consequences of fractures and their impact on quality of life. Am J Med. 1997;103(2A):12S-19S.
33. Guralnik JM, Alecxih L, Branch LG, Wiener JM. Medical and long-term care costs when older persons become more dependent. Am J Public Health. 2002;92(8):1244-1245.